Duodenal
somatostatinoma is the second most common (18%) neuroendocrine tumor of the duodenum and is associated with neurofibromatosis type 1 in one-third of cases.
The common types of functional NETs include carcinoid, insulinoma, gastrinoma, glucagonoma, VIPoma, and
somatostatinoma. Non-functional NETs are commonly slow growing and may only come to clinical detection when they are widely metastatic due to their slow onset of symptom.
These include insulinoma, gastrinoma, VIPoma,
somatostatinoma, and glucagonoma.
Unlike other pNET, such as gastrinoma or
somatostatinoma, insulinomas are usually benign, so it is possible to speculate that this peculiar behavior could be attributed to particular oncogenic events.
Other GI manifestations of NF-1 in patients listed in Table 1 included one or multiple small-bowel GISTs (two patients), duodenal
somatostatinoma (one patient), duodenal hyperplastic-inflammatory polyp (one patient), interstitial cell of Cajal hyperplasia (one patient), cecal inflammatory polyp (one patient), and angiomatous colonic polyp (one patient).
Recently, NT-proSST has been shown to be a potential marker for acute heart failure and mortality in an unselected patient cohort presented to an emergency department (5, 16) and for the diagnosis of
somatostatinoma in humans (17).
En sik insulinoma olmak uzere sirasiyla gastrinoma, glukagonoma, VIPoma,
somatostatinoma ve diger nadir PNET'ler bu gruba dahildir.
(8.) The medical subject Headings indexing system refers to "islet cell carcinoma", which is subdivided into gastrinoma, glucagonoma,
somatostatinoma and VIPoma.
In turn, a significant diabetic etiology component is manifested in GK rats, which much more resembles secondary diabetes mellitus observed in
somatostatinoma or states after treatment with somatostatin analogs [46, 47].
The syndrome of PHEO/PGL and
somatostatinoma associated with polycythemia, caused by HIF2A mutations, is a new PHEO-associated cancer syndrome described initially in 2012 [71].
There are also other types of diabetes which are considered as secondary to other conditions, for example, any damage to pancreas such as removal of pancreatic tissue, trauma, pancreatic carcinoma, and infection, or underlying diseases including endocrine diseases that alter different hormones secretion which are antagonist to insulin resulting in various clinical manifestations such as acromegaly, Cushing's syndrome, pheochromocytoma, glucagonoma,
somatostatinoma, and diabetes.
Calcification have been described in various neoplasm associated with hormone production including duodenal
Somatostatinoma, carcinoid tumour, prolactinoma, calcifying Sertoli cell tumour and gonadoblastoma [3].
